title: Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor through matrix metalloproteinase 14 pathway in PANC-1 cells.
abstract: OBJECTIVE
  To investigate whether celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, can attenuate proliferation, migration, invasion and MMP-14 expression in pancreatic cancer cells PANC-1 and the possible anti-tumor mechanism of celecoxib.
  
  
  METHODS
  Human pancreatic cancer cell line PANC-1 cells were treated with diverse concentrations of celecoxib (20, 60, 100 μmol/L). Cell proliferation, invasion and migration capabilities were measured by MTT colorimetry, transwell invasion assay, and scratch assay separately. At the same time, the protein expression of COX-2 and MMP-14 was assessed by ELISA.
  
  
  RESULTS
  The capabilities of proliferation, invasion and migration in PANC-1 cells were attenuated in a concentration-dependent manner after treated with celecoxib, followed by the down-regulation of the protein expression of COX-2 and MMP-14. In addition, MMP-14 expression was significantly positively correlated with COX-2 expression.
  
  
  CONCLUSIONS
  COX-2 inhibitor celecoxib can inhibit the proliferation, invasion and migration of PANC-1 cells via down-regulating the expression of MMP-14 in a concentration-dependent manner, thus contributing to its anti-tumor effect in pancreatic cancer.
authors.affiliation: Medical College of Shihezi University, Key Laboratory of Ministry of Education, Xinjiang Endemic and Ethnic Diseases Shihezi 832002, China.
authors.forename: Siyuan
authors.initials: S
authors.lastname: Li
authors.affiliation: Medical College of Shihezi University, Key Laboratory of Ministry of Education, Xinjiang Endemic and Ethnic Diseases Shihezi 832002, China.
authors.forename: Zhuoyu
authors.initials: Z
authors.lastname: Gu
authors.affiliation: Medical College of Shihezi University, Key Laboratory of Ministry of Education, Xinjiang Endemic and Ethnic Diseases Shihezi 832002, China.
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Xiao
authors.affiliation: Key Laboratory, First Affiliated Hospital, Medical College of Shihezi University Shihezi 832002, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.affiliation: Department of Endocrinology, First Affiliated Hospital, Medical College of Shihezi University Shihezi 832002, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Endocrinology, First Affiliated Hospital, Medical College of Shihezi University Shihezi 832002, China.
authors.forename: Kan
authors.initials: K
authors.lastname: Sun
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D000068579:Celecoxib / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D015536:Down-Regulation; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D053511:Matrix Metalloproteinase 14 / Q000096:biosynthesis*; D009361:Neoplasm Invasiveness / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D051546:Cyclooxygenase 2; C507086:MMP14 protein, human; D053511:Matrix Metalloproteinase 14; D000068579:Celecoxib
keywords: Pancreatic cancer; celecoxib; cyclooxygenase-2; matrix metalloproteinase-14